Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:PCGF3-ACTR3

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: PCGF3-ACTR3
	FusionPDB ID: 63287
	FusionGDB2.0 ID: 63287
		Hgene	Tgene
	Gene symbol	PCGF3	ACTR3
	Gene ID	10336	10096
	Gene name	polycomb group ring finger 3	actin related protein 3
	Synonyms	DONG1\|RNF3\|RNF3A	ARP3
	Cytomap	4p16.3	2q14.1
	Type of gene	protein-coding	protein-coding
	Description	polycomb group RING finger protein 3RING finger protein 3Aring finger protein 3	actin-related protein 3ARP3 actin related protein 3 homologactin-like protein 3
	Modification date	20200313	20200327
	UniProtAcc	.	Q9C0K3 Main function of 5'-partner protein: FUNCTION: May play a role in the suppression of metastatic potential in lung adenoma carcinoma cells. {ECO:0000269\|PubMed:11162478}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000362003, ENST00000470161, ENST00000505655, ENST00000521023, ENST00000400151, ENST00000482726,	ENST00000263238, ENST00000535589, ENST00000536059,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	14 X 8 X 8=896	16 X 13 X 7=1456
	# samples	18	17
	** MAII score	log2(18/896*10)=-2.31550182572793 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(17/1456*10)=-3.098403704061 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: PCGF3 [Title/Abstract] AND ACTR3 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: PCGF3 [Title/Abstract] AND ACTR3 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	PCGF3(738476)-ACTR3(114709056), # samples:1
Anticipated loss of major functional domain due to fusion event.	PCGF3-ACTR3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PCGF3-ACTR3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PCGF3-ACTR3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. PCGF3-ACTR3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	ACTR3	GO:0034314	Arp2/3 complex-mediated actin nucleation	11741539\|17220302
Tgene	ACTR3	GO:0045944	positive regulation of transcription by RNA polymerase II	17220302

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr4:738476/chr2:114709056)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across PCGF3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ACTR3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000362003	PCGF3	chr4	738476	+	ENST00000263238	ACTR3	chr2	114709056	+	6397	857	395	1255	286
ENST00000362003	PCGF3	chr4	738476	+	ENST00000536059	ACTR3	chr2	114709056	+	1371	857	395	1255	286
ENST00000362003	PCGF3	chr4	738476	+	ENST00000535589	ACTR3	chr2	114709056	+	1392	857	395	1255	286
ENST00000470161	PCGF3	chr4	738476	+	ENST00000263238	ACTR3	chr2	114709056	+	6396	856	394	1254	286
ENST00000470161	PCGF3	chr4	738476	+	ENST00000536059	ACTR3	chr2	114709056	+	1370	856	394	1254	286
ENST00000470161	PCGF3	chr4	738476	+	ENST00000535589	ACTR3	chr2	114709056	+	1391	856	394	1254	286
ENST00000521023	PCGF3	chr4	738476	+	ENST00000263238	ACTR3	chr2	114709056	+	7365	1825	1462	2223	253
ENST00000521023	PCGF3	chr4	738476	+	ENST00000536059	ACTR3	chr2	114709056	+	2339	1825	1462	2223	253
ENST00000521023	PCGF3	chr4	738476	+	ENST00000535589	ACTR3	chr2	114709056	+	2360	1825	1462	2223	253
ENST00000505655	PCGF3	chr4	738476	+	ENST00000263238	ACTR3	chr2	114709056	+	6046	506	44	904	286
ENST00000505655	PCGF3	chr4	738476	+	ENST00000536059	ACTR3	chr2	114709056	+	1020	506	44	904	286
ENST00000505655	PCGF3	chr4	738476	+	ENST00000535589	ACTR3	chr2	114709056	+	1041	506	44	904	286

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000362003	ENST00000263238	PCGF3	chr4	738476	+	ACTR3	chr2	114709056	+	0.000127931	0.9998721
ENST00000362003	ENST00000536059	PCGF3	chr4	738476	+	ACTR3	chr2	114709056	+	0.002372526	0.99762744
ENST00000362003	ENST00000535589	PCGF3	chr4	738476	+	ACTR3	chr2	114709056	+	0.00218441	0.9978156
ENST00000470161	ENST00000263238	PCGF3	chr4	738476	+	ACTR3	chr2	114709056	+	0.000126482	0.9998735
ENST00000470161	ENST00000536059	PCGF3	chr4	738476	+	ACTR3	chr2	114709056	+	0.002386968	0.9976131
ENST00000470161	ENST00000535589	PCGF3	chr4	738476	+	ACTR3	chr2	114709056	+	0.002207969	0.997792
ENST00000521023	ENST00000263238	PCGF3	chr4	738476	+	ACTR3	chr2	114709056	+	0.000497374	0.99950266
ENST00000521023	ENST00000536059	PCGF3	chr4	738476	+	ACTR3	chr2	114709056	+	0.002977486	0.99702245
ENST00000521023	ENST00000535589	PCGF3	chr4	738476	+	ACTR3	chr2	114709056	+	0.002820454	0.9971795
ENST00000505655	ENST00000263238	PCGF3	chr4	738476	+	ACTR3	chr2	114709056	+	0.000113262	0.99988675
ENST00000505655	ENST00000536059	PCGF3	chr4	738476	+	ACTR3	chr2	114709056	+	0.001872114	0.9981279
ENST00000505655	ENST00000535589	PCGF3	chr4	738476	+	ACTR3	chr2	114709056	+	0.001803378	0.99819666

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PCGF3-ACTR3

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
PCGF3	chr4	738476	ACTR3	chr2	114709056	1825	120	KPEEDNDYHRSDEQFANPDFTQPISE
PCGF3	chr4	738476	ACTR3	chr2	114709056	506	153	KPEEDNDYHRSDEQFANPDFTQPISE
PCGF3	chr4	738476	ACTR3	chr2	114709056	856	153	KPEEDNDYHRSDEQFANPDFTQPISE
PCGF3	chr4	738476	ACTR3	chr2	114709056	857	153	KPEEDNDYHRSDEQFANPDFTQPISE

Top

Potential FusionNeoAntigen Information of PCGF3-ACTR3 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

PCGF3-ACTR3_738476_114709056.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B15:18	YHRSDEQF	0.9565	0.7547	7	15
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B38:02	YHRSDEQF	0.9208	0.922	7	15
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B15:10	YHRSDEQF	0.919	0.5975	7	15
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B38:01	YHRSDEQF	0.91	0.9242	7	15
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B15:37	YHRSDEQF	0.8491	0.7337	7	15
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B18:01	DEQFANPDF	0.9874	0.8805	11	20
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B39:06	YHRSDEQFA	0.9804	0.7055	7	16
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B73:01	HRSDEQFANP	0.9659	0.7192	8	18
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B38:05	YHRSDEQF	0.91	0.9242	7	15
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B18:04	DEQFANPDF	0.9913	0.8989	11	20
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B18:07	DEQFANPDF	0.9898	0.8503	11	20
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B18:05	DEQFANPDF	0.9874	0.8805	11	20
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B18:08	DEQFANPDF	0.9862	0.8384	11	20
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B18:06	DEQFANPDF	0.9827	0.8821	11	20
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B18:03	DEQFANPDF	0.9811	0.8722	11	20
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B18:11	DEQFANPDF	0.7423	0.7431	11	20
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	HLA-B57:02	RSDEQFANPDF	0.9982	0.8938	9	20

Top

Potential FusionNeoAntigen Information of PCGF3-ACTR3 in HLA II

PCGF3-ACTR3_738476_114709056.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0901	DNDYHRSDEQFANPD	4	19
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0901	EDNDYHRSDEQFANP	3	18
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0901	EEDNDYHRSDEQFAN	2	17
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0901	NDYHRSDEQFANPDF	5	20
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0902	DNDYHRSDEQFANPD	4	19
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0902	EDNDYHRSDEQFANP	3	18
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0903	DNDYHRSDEQFANPD	4	19
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0903	EDNDYHRSDEQFANP	3	18
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0903	EEDNDYHRSDEQFAN	2	17
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0904	DNDYHRSDEQFANPD	4	19
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0904	EDNDYHRSDEQFANP	3	18
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0904	EEDNDYHRSDEQFAN	2	17
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0905	DNDYHRSDEQFANPD	4	19
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0905	EDNDYHRSDEQFANP	3	18
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0907	DNDYHRSDEQFANPD	4	19
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0907	EDNDYHRSDEQFANP	3	18
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0907	EEDNDYHRSDEQFAN	2	17
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0907	NDYHRSDEQFANPDF	5	20
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0908	DNDYHRSDEQFANPD	4	19
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0908	EDNDYHRSDEQFANP	3	18
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0908	EEDNDYHRSDEQFAN	2	17
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0908	NDYHRSDEQFANPDF	5	20
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0909	DNDYHRSDEQFANPD	4	19
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0909	EDNDYHRSDEQFANP	3	18
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0909	EEDNDYHRSDEQFAN	2	17
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB1-0909	NDYHRSDEQFANPDF	5	20
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB5-0112	DNDYHRSDEQFANPD	4	19
PCGF3-ACTR3	chr4	738476	chr2	114709056	857	DRB5-0112	EDNDYHRSDEQFANP	3	18

Top

Fusion breakpoint peptide structures of PCGF3-ACTR3

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
1492	DYHRSDEQFANPDF	PCGF3	ACTR3	chr4	738476	chr2	114709056	857

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PCGF3-ACTR3

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	1492	DYHRSDEQFANPDF	-7.15543	-7.26883
HLA-B14:02	3BVN	1492	DYHRSDEQFANPDF	-4.77435	-5.80965
HLA-B52:01	3W39	1492	DYHRSDEQFANPDF	-6.80875	-6.92215
HLA-B52:01	3W39	1492	DYHRSDEQFANPDF	-4.20386	-5.23916
HLA-A11:01	4UQ2	1492	DYHRSDEQFANPDF	-7.5194	-8.5547
HLA-A11:01	4UQ2	1492	DYHRSDEQFANPDF	-6.9601	-7.0735
HLA-A24:02	5HGA	1492	DYHRSDEQFANPDF	-7.52403	-7.63743
HLA-A24:02	5HGA	1492	DYHRSDEQFANPDF	-5.82433	-6.85963
HLA-B27:05	6PYJ	1492	DYHRSDEQFANPDF	-3.28285	-4.31815
HLA-B44:05	3DX8	1492	DYHRSDEQFANPDF	-5.91172	-6.94702
HLA-B44:05	3DX8	1492	DYHRSDEQFANPDF	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of PCGF3-ACTR3

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
PCGF3-ACTR3	chr4	738476	chr2	114709056	11	20	DEQFANPDF	GAGCAGTTTGCTAATCCAGACTTTACA
PCGF3-ACTR3	chr4	738476	chr2	114709056	7	15	YHRSDEQF	CACCGCAGCGACGAGCAGTTTGCT
PCGF3-ACTR3	chr4	738476	chr2	114709056	7	16	YHRSDEQFA	CACCGCAGCGACGAGCAGTTTGCTAAT
PCGF3-ACTR3	chr4	738476	chr2	114709056	8	18	HRSDEQFANP	CGCAGCGACGAGCAGTTTGCTAATCCAGAC
PCGF3-ACTR3	chr4	738476	chr2	114709056	9	20	RSDEQFANPDF	AGCGACGAGCAGTTTGCTAATCCAGACTTTACA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
PCGF3-ACTR3	chr4	738476	chr2	114709056	2	17	EEDNDYHRSDEQFAN	GAGGACAACGACTACCACCGCAGCGACGAGCAGTTTGCTAATCCA
PCGF3-ACTR3	chr4	738476	chr2	114709056	3	18	EDNDYHRSDEQFANP	GACAACGACTACCACCGCAGCGACGAGCAGTTTGCTAATCCAGAC
PCGF3-ACTR3	chr4	738476	chr2	114709056	4	19	DNDYHRSDEQFANPD	AACGACTACCACCGCAGCGACGAGCAGTTTGCTAATCCAGACTTT
PCGF3-ACTR3	chr4	738476	chr2	114709056	5	20	NDYHRSDEQFANPDF	GACTACCACCGCAGCGACGAGCAGTTTGCTAATCCAGACTTTACA

Top

Information of the samples that have these potential fusion neoantigens of PCGF3-ACTR3

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
STAD	PCGF3-ACTR3	chr4	738476	ENST00000362003	chr2	114709056	ENST00000263238	TCGA-BR-A4J5-01A

Top

Potential target of CAR-T therapy development for PCGF3-ACTR3

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to PCGF3-ACTR3

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to PCGF3-ACTR3

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)